{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:00:41Z","timestamp":1771862441557,"version":"3.50.1"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"crossref","award":["Z04JKM2023E040"],"award-info":[{"award-number":["Z04JKM2023E040"]}],"id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00228-025-03987-4","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:13:31Z","timestamp":1768806811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Zanubrutinib in B-cell lymphomas: from clinical pharmacology to therapeutic application"],"prefix":"10.1007","volume":"82","author":[{"given":"Tian-Bo","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ting","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu-Ning","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Jiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"12","key":"3987_CR1","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/nri955","volume":"2","author":"H Niiro","year":"2002","unstructured":"Niiro H, Clark EA (2002) Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2(12):945\u2013956. https:\/\/doi.org\/10.1038\/nri955","journal-title":"Nat Rev Immunol"},{"key":"3987_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fimmu.2020.00045","volume":"11","author":"W Liu","year":"2020","unstructured":"Liu W, Tolar P, Song W, Kim TJ (2020) Editorial: BCR signaling and B cell activation. Front Immunol 11:45. https:\/\/doi.org\/10.3389\/fimmu.2020.00045","journal-title":"Front Immunol"},{"issue":"2","key":"3987_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","volume":"35","author":"T Wen","year":"2021","unstructured":"Wen T, Wang J, Shi Y, Qian H, Liu P (2021) Inhibitors targeting bruton\u2019s tyrosine kinase in cancers: drug development advances. Leukemia 35(2):312\u2013332. https:\/\/doi.org\/10.1038\/s41375-020-01072-6","journal-title":"Leukemia"},{"issue":"1","key":"3987_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s40265-017-0852-8","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham A, Dhillon S (2018) Acalabrutinib: first global approval. Drugs 78(1):139\u2013145. https:\/\/doi.org\/10.1007\/s40265-017-0852-8","journal-title":"Drugs"},{"issue":"1","key":"3987_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY (2020) Zanubrutinib: first approval. Drugs 80(1):91\u201397. https:\/\/doi.org\/10.1007\/s40265-019-01252-4","journal-title":"Drugs"},{"issue":"6","key":"3987_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40265-023-01860-1","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023) Pirtobrutinib: first approval. Drugs 83(6):547\u2013553. https:\/\/doi.org\/10.1007\/s40265-023-01860-1","journal-title":"Drugs"},{"issue":"17","key":"3987_CR7","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","volume":"62","author":"Y Guo","year":"2019","unstructured":"Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, Zhang B, Wei M, Liu J, Luo L, Tang Z, Song H, Guo Y, Liu X, Su D, Zhang S, Song X, Zhou X, Hong Y, Chen S, Cheng Z, Young S, Wei Q, Wang H, Wang Q, Lv L, Wang F, Xu H, Sun H, Xing H, Li N, Zhang W, Wang Z, Liu G, Sun Z, Zhou D, Li W, Liu L, Wang L, Wang Z (2019) Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of bruton\u2019s tyrosine kinase. J Med Chem 62(17):7923\u20137940. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00687","journal-title":"J Med Chem"},{"issue":"6","key":"3987_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","volume":"23","author":"CU Niemann","year":"2013","unstructured":"Niemann CU, Wiestner A (2013) B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 23(6):410\u2013421. https:\/\/doi.org\/10.1016\/j.semcancer.2013.09.001","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"3987_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"SS Pal","year":"2018","unstructured":"Pal SS, Dammeijer F, Hendriks RW (2018) Role of bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer 17(1):57. https:\/\/doi.org\/10.1186\/s12943-018-0779-z","journal-title":"Mol Cancer"},{"key":"3987_CR10","doi-asserted-by":"publisher","unstructured":"Li N, Sun Z, Liu Y, Guo M, Zhang Y, Zhou D, Zhang B, Su D, Zhang S, Han J, Gao Y, Guo Y, Wang Z, Wei M, Luo L, Wang L (2015) BGB-3111 is a novel and highly selective Bruton\u2019s tyrosine kinase (BTK) inhibitor. Cancer Res 7515. https:\/\/doi.org\/10.1158\/1538-7445.AM2015-2597","DOI":"10.1158\/1538-7445.AM2015-2597"},{"issue":"4","key":"3987_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/hon.2667","volume":"37","author":"YX Zou","year":"2019","unstructured":"Zou YX, Zhu HY, Li XT, Xia Y, Miao KR, Zhao SS, Wu YJ, Wang L, Xu W, Li JY (2019) The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma. Hematol Oncol 37(4):392\u2013400. https:\/\/doi.org\/10.1002\/hon.2667","journal-title":"Hematol Oncol"},{"issue":"11","key":"3987_CR12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/17512433.2021.1978288","volume":"14","author":"CS Tam","year":"2021","unstructured":"Tam CS, Ou YC, Trotman J, Opat S (2021) Clinical pharmacology and PK\/PD translation of the second-generation bruton\u2019s tyrosine kinase inhibitor, zanubrutinib. Expert Rev Clin Pharmacol 14(11):1329\u20131344. https:\/\/doi.org\/10.1080\/17512433.2021.1978288","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"11","key":"3987_CR13","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW (2019) Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood 134(11):851\u2013859. https:\/\/doi.org\/10.1182\/blood.2019001160","journal-title":"Blood"},{"issue":"1","key":"3987_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.18162","volume":"198","author":"Y Song","year":"2022","unstructured":"Song Y, Sun M, Qi J, Xu W, Zhou J, Li D, Li J, Qiu L, Du C, Guo H, Huang J, Tang Z, Ou Y, Wu B, Yu Y, Zhu J (2022) A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed\/refractory B-cell malignancies. Br J Haematol 198(1):62\u201372. https:\/\/doi.org\/10.1111\/bjh.18162","journal-title":"Br J Haematol"},{"issue":"6","key":"3987_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","volume":"31","author":"MS Lionakis","year":"2017","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH (2017) Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell 31(6):833\u2013843. https:\/\/doi.org\/10.1016\/j.ccell.2017.04.012","journal-title":"Cancer Cell"},{"key":"3987_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.760405","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Li Y, Zhuang Z, Wang W, Wei C, Zhao D, Zhou D, Zhang W (2021) Preliminary evaluation of zanubrutinib-containing regimens in DLBCL and the cerebrospinal fluid distribution of zanubrutinib: a 13-case series. Front Oncol 11:760405. https:\/\/doi.org\/10.3389\/fonc.2021.760405","journal-title":"Front Oncol"},{"issue":"1","key":"3987_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12185-015-1900-3","volume":"103","author":"K Tobinai","year":"2016","unstructured":"Tobinai K, Ogura M, Ishizawa K, Suzuki T, Munakata W, Uchida T, Aoki T, Morishita T, Ushijima Y, Takahara S (2016) Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed\/refractory B cell malignancies. Int J Hematol 103(1):86\u201394. https:\/\/doi.org\/10.1007\/s12185-015-1900-3","journal-title":"Int J Hematol"},{"key":"3987_CR18","unstructured":"U.S. Food and Drug Administration. Approval label for BRUKINSA\u00ae(Revised:1\/2025). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/213217s015lbl.pdf."},{"key":"3987_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.676792","volume":"11","author":"L Wang","year":"2021","unstructured":"Wang L, Guan W, Peng X (2021) Targeting Bruton Tyrosine Kinase with Zanubrutinib for treatment of vitreoretinal lymphoma: report of 3 cases. Front Oncol 11:676792. https:\/\/doi.org\/10.3389\/fonc.2021.676792","journal-title":"Front Oncol"},{"issue":"1","key":"3987_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000529315","volume":"16","author":"Y Liu","year":"2023","unstructured":"Liu Y, Sun J, Tuo K (2023) Zanubrutinib in the maintenance treatment of elderly people with primary central nervous system lymphoma: a report of 2 cases. Case Rep Oncol 16(1):227\u2013233. https:\/\/doi.org\/10.1159\/000529315","journal-title":"Case Rep Oncol"},{"issue":"6","key":"3987_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.870","volume":"9","author":"H Zhang","year":"2021","unstructured":"Zhang H, Ou YC, Su D, Wang F, Wang L, Sahasranaman S, Tang Z (2021) In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton\u2019s tyrosine kinase inhibitor. Pharmacology Research & Perspectives 9(6):e00870. https:\/\/doi.org\/10.1002\/prp2.870","journal-title":"Pharmacology Research & Perspectives"},{"issue":"8","key":"3987_CR22","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/cpdd.1250","volume":"12","author":"B Tariq","year":"2023","unstructured":"Tariq B, Conto S, Cohen A, Sahasranaman S, Ou YC (2023) A phase 1, open-label, fixed-sequence, drug-drug interaction study of zanubrutinib with Rifabutin in healthy volunteers. Clin Pharm Drug Dev 12(8):832\u2013838. https:\/\/doi.org\/10.1002\/cpdd.1250","journal-title":"Clin Pharm Drug Dev"},{"issue":"2","key":"3987_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00280-019-04015-w","volume":"85","author":"S Mu","year":"2020","unstructured":"Mu S, Tang Z, Novotny W, Tawashi M, Li TK, Ou Y, Sahasranaman S (2020) Effect of Rifampin and Itraconazole on the pharmacokinetics of zanubrutinib (a bruton\u2019s tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects. Cancer Chemoth Pharm 85(2):391\u2013399. https:\/\/doi.org\/10.1007\/s00280-019-04015-w","journal-title":"Cancer Chemoth Pharm"},{"issue":"5","key":"3987_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/psp4.12605","volume":"10","author":"K Wang","year":"2021","unstructured":"Wang K, Yao X, Zhang M, Liu D, Gao Y, Sahasranaman S, Ou YC (2021) Comprehensive PBPK model to predict drug interaction potential of zanubrutinib as a victim or perpetrator. Cpt-Pharmacomet Syst 10(5):441\u2013454. https:\/\/doi.org\/10.1002\/psp4.12605","journal-title":"Cpt-Pharmacomet Syst"},{"issue":"7","key":"3987_CR25","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1111\/bcp.14707","volume":"87","author":"YC Ou","year":"2021","unstructured":"Ou YC, Tang Z, Novotny W, Tawashi M, Li TK, Coleman HA, Sahasranaman S (2021) Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP. Br J Clin Pharmacol 87(7):2926\u20132936. https:\/\/doi.org\/10.1111\/bcp.14707","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3987_CR26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00280-020-04137-6","volume":"86","author":"KM Fancher","year":"2020","unstructured":"Fancher KM, Pappacena JJ (2020) Drug interactions with bruton\u2019s tyrosine kinase inhibitors: clinical implications and management. Cancer Chemoth Pharm 86(4):507\u2013515. https:\/\/doi.org\/10.1007\/s00280-020-04137-6","journal-title":"Cancer Chemoth Pharm"},{"key":"3987_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106564","volume":"189","author":"C Li","year":"2023","unstructured":"Li C, Chen L, Li L, Chen W (2023) Drug-drug interactions and dose management of BTK inhibitors when initiating nirmatrelvir\/ritonavir (paxlovid) based on physiologically-based pharmacokinetic models. Eur J Pharm Sci 189:106564. https:\/\/doi.org\/10.1016\/j.ejps.2023.106564","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"3987_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/10428194.2022.2150820","volume":"64","author":"B Tariq","year":"2023","unstructured":"Tariq B, Ou YC, Stern JC, Mundra V, Wong DN, Walker P, Lewis KL, Lin C, Novotny W, Sahasranaman S, Opat S (2023) A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies. Leuk Lymphoma 64(2):329\u2013338. https:\/\/doi.org\/10.1080\/10428194.2022.2150820","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"3987_CR29","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s40262-020-00884-0","volume":"59","author":"F Gallais","year":"2020","unstructured":"Gallais F, Ysebaert L, Despas F, De Barros S, Dupre L, Quillet-Mary A, Protin C, Thomas F, Oberic L, Allal B, Chatelut E, White-Koning M (2020) Population pharmacokinetics of ibrutinib and its dihydrodiol metabolite in patients with lymphoid malignancies. Clin Pharmacokinet 59(9):1171\u20131183. https:\/\/doi.org\/10.1007\/s40262-020-00884-0","journal-title":"Clin Pharmacokinet"},{"key":"3987_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109559","volume":"345","author":"M Han","year":"2021","unstructured":"Han M, Qian J, Ye Z, Xu R, Chen D, Xie S, Cai J, Hu G (2021) Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro. Chem-Biol Interact 345:109559. https:\/\/doi.org\/10.1016\/j.cbi.2021.109559","journal-title":"Chem-Biol Interact"},{"issue":"2","key":"3987_CR31","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/cts.12948","volume":"14","author":"YC Ou","year":"2021","unstructured":"Ou YC, Liu L, Tariq B, Wang K, Jindal A, Tang Z, Gao Y, Sahasranaman S (2021) Population pharmacokinetic analysis of the BTK inhibitor zanubrutinib in healthy volunteers and patients with B-Cell malignancies. CTS-Clin Transl Sci 14(2):764\u2013772. https:\/\/doi.org\/10.1111\/cts.12948","journal-title":"CTS-Clin Transl Sci"},{"issue":"6","key":"3987_CR32","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1080\/10428194.2020.1719097","volume":"61","author":"YC Ou","year":"2020","unstructured":"Ou YC, Preston RA, Marbury TC, Tang Z, Novotny W, Tawashi M, Li TK, Sahasranaman S (2020) A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment. Leuk Lymphoma 61(6):1355\u20131363. https:\/\/doi.org\/10.1080\/10428194.2020.1719097","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"3987_CR33","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1080\/10428194.2021.1929961","volume":"62","author":"YC Ou","year":"2021","unstructured":"Ou YC, Tang Z, Novotny W, Cohen A, Wang K, Liu L, Gao Y, Sahasranaman S (2021) Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma. Leuk Lymphoma 62(11):2612\u20132624. https:\/\/doi.org\/10.1080\/10428194.2021.1929961","journal-title":"Leuk Lymphoma"},{"issue":"134","key":"3987_CR34","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.1182\/blood-2019-129580","volume":"1","author":"Y Ou","year":"2019","unstructured":"Ou Y, Wang K, Liu L, Jindal A, Gao Y, Sahasranaman S (2019) Exposure-response relationship of the Bruton tyrosine kinase inhibitor, zanubrutinib (BGB-3111) in patients with hematologic malignancies. Blood Supplement 1(134):5063. https:\/\/doi.org\/10.1182\/blood-2019-129580","journal-title":"Blood Supplement"},{"issue":"5","key":"3987_CR35","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/cts.12779","volume":"13","author":"S Mu","year":"2020","unstructured":"Mu S, Darpo B, Tang Z, Novotny W, Tawashi M, Xue H, Willett M, Lin L, Sahasranaman S, Ou YC (2020) No QTc prolongation with zanubrutinib: results of concentration-QTc analysis from a thorough QT study in healthy subjects. Clin Transl Sci 13(5):923\u2013931. https:\/\/doi.org\/10.1111\/cts.12779","journal-title":"Clin Transl Sci"},{"key":"3987_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28031205","author":"LN Sun","year":"2023","unstructured":"Sun LN, Zhao Y, Qian ZY, Chen XL, Ma H, Guo YJ, Shen H, Wang YQ (2023) Simultaneous determination of Orelabrutinib, Zanubrutinib, Ibrutinib and its active metabolite in human plasma using LC-MS\/MS. Molecules. https:\/\/doi.org\/10.3390\/molecules28031205","journal-title":"Molecules"},{"issue":"5","key":"3987_CR37","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cpt.787","volume":"102","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Yu H, Schellens J, Beijnen JH, Steeghs N, Huitema A (2017) Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther 102(5):765\u2013776. https:\/\/doi.org\/10.1002\/cpt.787","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl_1","key":"3987_CR38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-109973","volume":"132","author":"A Kaptein","year":"2018","unstructured":"Kaptein A, Bruin GD, Hoek EV, Kar BVD, Barf T (2018) Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies. Blood 132(Suppl_1):1871","journal-title":"Blood"},{"key":"3987_CR39","doi-asserted-by":"publisher","first-page":"630942","DOI":"10.3389\/fcell.2021.630942","volume":"9","author":"HY Estupinan","year":"2021","unstructured":"Estupinan HY, Berglof A, Zain R, Smith C (2021) Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol 9:630942. https:\/\/doi.org\/10.3389\/fcell.2021.630942","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"3987_CR40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood.2022018674","volume":"142","author":"EB Gomez","year":"2023","unstructured":"Gomez EB, Ebata K, Randeria HS, Rosendahl MS, Cedervall EP, Morales TH, Hanson LM, Brown NE, Gong X, Stephens J, Wu W, Lippincott I, Ku KS, Walgren RA, Abada PB, Ballard JA, Allerston CK, Brandhuber BJ (2023) Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood 142(1):62\u201372. https:\/\/doi.org\/10.1182\/blood.2022018674","journal-title":"Blood"},{"issue":"11","key":"3987_CR41","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","volume":"123","author":"ZR Hunter","year":"2014","unstructured":"Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Manning RJ, Tripsas C, Patterson CJ, Sheehy P, Treon SP (2014) The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 123(11):1637\u20131646. https:\/\/doi.org\/10.1182\/blood-2013-09-525808","journal-title":"Blood"},{"issue":"18","key":"3987_CR42","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1182\/blood.2020006449","volume":"136","author":"J Trotman","year":"2020","unstructured":"Trotman J, Opat S, Gottlieb D, Simpson D, Marlton P, Cull G, Munoz J, Tedeschi A, Roberts AW, Seymour JF, Atwal SK, Yu Y, Novotny W, Holmgren E, Tan Z, Hilger JD, Huang J, Tam CS (2020) Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up. Blood 136(18):2027\u20132037. https:\/\/doi.org\/10.1182\/blood.2020006449","journal-title":"Blood"},{"issue":"7","key":"3987_CR43","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1182\/bloodadvances.2023010906","volume":"8","author":"CS Tam","year":"2024","unstructured":"Tam CS, Opat S, D\u2019Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Garcia-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernandez DLC, Belada D, Libby E, Matous J, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Treon SP, Trotman J, Wu B, Yu Y, Shen Z, Chan WY, Schneider J, Allewelt H, Cohen A, Dimopoulos MA (2024) Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstrom macroglobulinemia. Blood Adv 8(7):1639\u20131650. https:\/\/doi.org\/10.1182\/bloodadvances.2023010906","journal-title":"Blood Adv"},{"key":"3987_CR44","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283861","author":"L Xu","year":"2024","unstructured":"Xu L, Shadman M, Flinn IW, Levy MY, Porter R, Burke JM, Zafar SF, Cultrera JL, Misleh J, Kingsley EC, Yimer HA, Freeman B, Chaudhry A, Tumula PK, Gandhi MD, Crescenzo R, By K, Cohen A, Chen DY, Idoine A, Manda S, Sharman JP, Ramakrishnan V (2024) Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and\/or acalabrutinib-intolerant patients with B-cell malignancies. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2023.283861","journal-title":"Haematologica"},{"issue":"5","key":"3987_CR45","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","volume":"35","author":"HY Estupinan","year":"2021","unstructured":"Estupinan HY, Wang Q, Berglof A, Schaafsma G, Shi Y, Zhou L, Mohammad DK, Yu L, Vihinen M, Zain R, Smith C (2021) BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. Leukemia 35(5):1317\u20131329. https:\/\/doi.org\/10.1038\/s41375-021-01123-6","journal-title":"Leukemia"},{"key":"3987_CR46","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015493","author":"M Shadman","year":"2025","unstructured":"Shadman M, Burke JM, Cultrera J, Yimer HA, Zafar SF, Misleh J, Rao SS, Farber CM, Cohen AC, Yao H, Idoine A, An Q, Flinn IW, Sharman JP (2025) Zanubrutinib is well tolerated and effective in CLL\/SLL patients intolerant of ibrutinib\/acalabrutinib: updated results. Blood Adv. https:\/\/doi.org\/10.1182\/bloodadvances.2024015493","journal-title":"Blood Adv"},{"issue":"24","key":"3987_CR47","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC (2014) Resistance mechanisms for the bruton\u2019s tyrosine kinase inhibitor ibrutinib. N Engl J Med 370(24):2286\u20132294. https:\/\/doi.org\/10.1056\/NEJMoa1400029","journal-title":"N Engl J Med"},{"issue":"2","key":"3987_CR48","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjh.18418","volume":"200","author":"S Nakhoda","year":"2023","unstructured":"Nakhoda S, Vistarop A, Wang YL (2023) Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol 200(2):137\u2013149. https:\/\/doi.org\/10.1111\/bjh.18418","journal-title":"Br J Haematol"},{"issue":"20","key":"3987_CR49","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","volume":"6","author":"P Blombery","year":"2022","unstructured":"Blombery P, Thompson ER, Lew TE, Tiong IS, Bennett R, Cheah CY, Lewis KL, Handunnetti SM, Tang C, Roberts A, Seymour JF, Tam CS (2022) Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. Blood Adv 6(20):5589\u20135592. https:\/\/doi.org\/10.1182\/bloodadvances.2022008325","journal-title":"Blood Adv"},{"issue":"134","key":"3987_CR50","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/blood-2019-125488","volume":"1","author":"SM Handunnetti","year":"2019","unstructured":"Handunnetti SM, Tang CPS, Nguyen T, Zhou X, Blombery P (2019) BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib. Blood Supplement 1(134):170. https:\/\/doi.org\/10.1182\/blood-2019-125488","journal-title":"Blood Supplement"},{"key":"3987_CR51","doi-asserted-by":"publisher","unstructured":"Sharp J, Shana\u2019Ah AY, Voorhees TJ, Bond DA, Sawalha Y, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Maddocks K, Jones D, Christian B, Epperla N (2025) Resistance mechanism for zanubrutinib in marginal zone lymphoma. J Natl Compr Canc Ne 23(7). https:\/\/doi.org\/10.6004\/jnccn.2025.7045","DOI":"10.6004\/jnccn.2025.7045"},{"issue":"2","key":"3987_CR52","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/ajh.27544","volume":"100","author":"S Molica","year":"2025","unstructured":"Molica S, Allsup D, Giannarelli D (2025) Prevalence of BTK and PLCG2 mutations in CLL patients with disease progression on BTK inhibitor therapy: a meta-analysis. Am J Hematol 100(2):334\u2013337. https:\/\/doi.org\/10.1002\/ajh.27544","journal-title":"Am J Hematol"},{"key":"3987_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063234","author":"S Mouhssine","year":"2024","unstructured":"Mouhssine S, Maher N, Matti BF, Alwan AF, Gaidano G (2024) Targeting BTK in B cell malignancies: from mode of action to resistance mechanisms. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25063234","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3987_CR54","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Simkovic M, Shadman M, Osterborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trneny M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P (2022) Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol 23(8):1031\u20131043. https:\/\/doi.org\/10.1016\/S1470-2045(22)00293-5","journal-title":"Lancet Oncol"},{"issue":"S2","key":"3987_CR55","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/hon.3163_154","volume":"41","author":"M Shadman","year":"2023","unstructured":"Shadman M, Munir T, Roback T, Brown JR, Kahl BS, Ghia P, Giannopoulos K, \u0160imkovi\u010d M, \u00d6sterborg A, Laurenti L, Walker P, Opat S, Ciepluch H, Greil R, Hanna M, Tani M, Trn\u011bn\u00fd M, Brander D, Flinn IW, Grosicki S, Verner E, Tedeschi A, De Guibert S, Tumyan G, Laribi K, Garc\u00eda JA, Li J, Tian T, Ramakrishnan V, Liu Y, Szeto A, Paik J, Cohen A, Tam CS, Jurczak W (2023) ZANUBRUTINIB (ZANU) versus bendamustine\u2009+\u2009rituximab (BR) in patients (PTS) with treatment-na\u00efve (TN) CLL\/SLL: extended follow-up of the SEQUOIA study. Hematol Oncol 41(S2):235\u2013238. https:\/\/doi.org\/10.1002\/hon.3163_154","journal-title":"Hematol Oncol"},{"key":"3987_CR56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02265","author":"M Shadman","year":"2024","unstructured":"Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Simkovic M, Osterborg A, Laurenti L, Walker PA, Opat SS, Ciepluch H, Greil R, Hanna M, Tani M, Trneny M, Brander D, Flinn IW, Grosicki S, Verner E, Tedeschi A, de Guibert S, Tumyan G, Laribi K, Garcia-Marco JA, Li JY, Tian T, Liu Y, Korolkiewicz R, Szeto A, Tam CS, Jurczak W (2024) Zanubrutinib versus Bendamustine and rituximab in patients with Treatment-Naive chronic lymphocytic Leukemia\/Small lymphocytic lymphoma: median 5-Year Follow-Up of SEQUOIA. J Clin Oncol: JCO2402265. https:\/\/doi.org\/10.1200\/JCO-24-02265","journal-title":"J Clin Oncol: JCO2402265"},{"issue":"4","key":"3987_CR57","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kazmierczak M, Lamanna N, O\u2019Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M (2023) Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 388(4):319\u2013332. https:\/\/doi.org\/10.1056\/NEJMoa2211582","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"3987_CR58","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood-2023-174289","volume":"142","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst BF, Lamanna N, O\u2019Brien SM, Tam CS, Qiu L, Ka\u017amierczak M, Jurczak W, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy AL, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Wang MDY, Salmi T, Wang L, Li J, Wu K, Cohen AC, Shadman M (2023) Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R\/R CLL\/SLL). Blood 142(Supplement 1):202. https:\/\/doi.org\/10.1182\/blood-2023-174289","journal-title":"Blood"},{"issue":"26","key":"3987_CR59","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1182\/blood.2024024667","volume":"144","author":"JR Brown","year":"2024","unstructured":"Brown JR, Eichhorst B, Lamanna N, O\u2019Brien SM, Tam CS, Qiu L, Jurczak W, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Wang M, Salmi T, Wang L, Li J, Wu K, Cohen A, Shadman M (2024) Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE. Blood 144(26):2706\u20132717. https:\/\/doi.org\/10.1182\/blood.2024024667","journal-title":"Blood"},{"key":"3987_CR60","doi-asserted-by":"publisher","first-page":"6540","DOI":"10.1182\/blood-2023-180477","volume":"142","author":"J Luo","year":"2023","unstructured":"Luo J, Zhang J, Liu L, Wei R, Yao Y, Xu M, Xu J, Shi J, Yang J, Hou J, Wang J, Mi J (2023) Real-world outcomes of zanubrutinib monotherapy in chronic lymphocytic leukemia: a multicenter retrospective study. Blood 142:6540. https:\/\/doi.org\/10.1182\/blood-2023-180477","journal-title":"Blood"},{"issue":"1","key":"3987_CR61","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13045-021-01174-3","volume":"14","author":"K Zhou","year":"2021","unstructured":"Zhou K, Zou D, Zhou J, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Zhou D, Tam CS, Simpson D, Wang M, Phillips TJ, Opat S, Huang Z, Lu H, Song Y, Song Y (2021) Zanubrutinib monotherapy in relapsed\/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. J Hematol Oncol 14(1):167. https:\/\/doi.org\/10.1186\/s13045-021-01174-3","journal-title":"J Hematol Oncol"},{"issue":"18","key":"3987_CR62","doi-asserted-by":"publisher","first-page":"18643","DOI":"10.1002\/cam4.6473","volume":"12","author":"Y Song","year":"2023","unstructured":"Song Y, Zhou K, Zou D, Li D, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Zhou D, Tam CS, Simpson D, Wang M, Phillips TJ, Opat S, Fang C, Sun S, Zhu J (2023) Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed\/refractory mantle cell lymphoma: an updated pooled analysis. Cancer Med 12(18):18643\u201318653. https:\/\/doi.org\/10.1002\/cam4.6473","journal-title":"Cancer Med"},{"issue":"23","key":"3987_CR63","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1080\/14796694.2025.2554354","volume":"21","author":"BD Shah","year":"2025","unstructured":"Shah BD, Xue M, Furnback W, Yang K (2025) Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting. Future Oncol 21(23):3043\u20133049. https:\/\/doi.org\/10.1080\/14796694.2025.2554354","journal-title":"Future Oncol"},{"issue":"33","key":"3987_CR64","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1200\/JCO.22.02830","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Opat S, D\u2019Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Garcia-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernandez DLC, Belada D, Libby E, Matous J, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Treon SP, Trotman J, Chan WY, Schneider J, Allewelt H, Patel S, Cohen A, Tam CS (2023) Zanubrutinib versus ibrutinib in symptomatic Waldenstrom macroglobulinemia: final analysis from the randomized phase III ASPEN study. J Clin Oncol 41(33):5099\u20135106. https:\/\/doi.org\/10.1200\/JCO.22.02830","journal-title":"J Clin Oncol"},{"issue":"6","key":"3987_CR65","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3760\/cma.j.issn.0253-2727.2023.06.008","volume":"44","author":"Y Tao","year":"2023","unstructured":"Tao Y, Xu YL, Wang S, Wang L, Zhao WL (2023) [The efficacy and safety of Bruton tyrosine kinase inhibitors as monotherapy in the treatment of newly diagnosed patients with Waldenstrom macroglobulinemia]. Zhonghua Xue Ye Xue Za Zhi 44(6):490\u2013494. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2023.06.008","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"22","key":"3987_CR66","doi-asserted-by":"publisher","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","volume":"7","author":"S Opat","year":"2023","unstructured":"Opat S, Tedeschi A, Hu B, Linton KM, McKay P, Leitch S, Coleman M, Zinzani PL, Jin J, Sun M, Sobieraj-Teague M, Browett P, Ke X, Thieblemont C, Ardeshna K, Bijou F, Walker P, Hawkes EA, Ho SJ, Zhou K, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J (2023) Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study. Blood Adv 7(22):6801\u20136811. https:\/\/doi.org\/10.1182\/bloodadvances.2023010668","journal-title":"Blood Adv"},{"issue":"33","key":"3987_CR67","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1200\/JCO.23.00775","volume":"41","author":"PL Zinzani","year":"2023","unstructured":"Zinzani PL, Mayer J, Flowers CR, Bijou F, De Oliveira AC, Song Y, Zhang Q, Merli M, Bouabdallah K, Ganly P, Zhang H, Johnson R, Martin GA, Provencio PM, Trneny M, Yuen S, Tilly H, Kingsley E, Tumyan G, Assouline SE, Auer R, Ivanova E, Kim P, Huang S, Delarue R, Trotman J (2023) ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J Clin Oncol 41(33):5107\u20135117. https:\/\/doi.org\/10.1200\/JCO.23.00775","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"3987_CR68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e20051","volume":"38","author":"H Yang","year":"2020","unstructured":"Yang H, Xiang B, Song Y, Zhang H, Zhao W, Zou D, Lv F, Bai O, Liu A, Li C, Tan Z, Wang W, Guo H, Novotny W, Huang JE, Li Y (2020) Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase II, single-arm, multicenter, study. J Clin Oncol 38(15_suppl):e20051. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e20051","journal-title":"J Clin Oncol"},{"key":"3987_CR69","doi-asserted-by":"publisher","first-page":"1015081","DOI":"10.3389\/fimmu.2022.1015081","volume":"13","author":"X Yuan","year":"2022","unstructured":"Yuan X, Li X, Huang Y, Jin X, Liu H, Zhao A, Zhang W, Qian W, Liang Y (2022) Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Front Immunol 13:1015081. https:\/\/doi.org\/10.3389\/fimmu.2022.1015081","journal-title":"Front Immunol"},{"issue":"5","key":"3987_CR70","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/10428194.2025.2451066","volume":"66","author":"Y Wang","year":"2025","unstructured":"Wang Y, Han J, Yin S, Yang S, Kang X, Zheng X, Duan L, Li S, Jiang B, Li W, Chen F (2025) Bruton\u2019s tyrosine kinase inhibitor zanubrutinib-based regimens in relapsed\/refractory primary diffuse large B-cell lymphoma of the central nervous system. Leuk Lymphoma 66(5):869\u2013878. https:\/\/doi.org\/10.1080\/10428194.2025.2451066","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"3987_CR71","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","volume":"6","author":"CS Tam","year":"2022","unstructured":"Tam CS, Dimopoulos M, Garcia-Sanz R, Trotman J, Opat S, Roberts AW, Owen R, Song Y, Xu W, Zhu J, Li J, Qiu L, D\u2019Sa S, Jurczak W, Cull G, Marlton P, Gottlieb D, Munoz J, Phillips T, Du C, Ji M, Zhou L, Guo H, Zhu H, Chan WY, Cohen A, Novotny W, Huang J, Tedeschi A (2022) Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv 6(4):1296\u20131308. https:\/\/doi.org\/10.1182\/bloodadvances.2021005621","journal-title":"Blood Adv"},{"key":"3987_CR72","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283846","author":"JR Brown","year":"2024","unstructured":"Brown JR, Ghia P, Jurczak W, Kahl BS, Lamanna N, Robak T, Shadman M, Tam CS, Qiu L, Paik J, Salmi T, Wang L, Zhang J, Zhang M, Cohen A, Ma H, Tedeschi A (2024) Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2023.283846","journal-title":"Haematologica"},{"issue":"1","key":"3987_CR73","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/ajh.27519","volume":"100","author":"J Luo","year":"2025","unstructured":"Luo J, Zhang J, Liu L, Wei R, Yao Y, Xu M, Shi J, Yang J, Hou J, Wang J, Mi JQ (2025) Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic leukemia\/small lymphocytic lymphoma: a multicenter, real-world study in China. Am J Hematol 100(1):172\u2013175. https:\/\/doi.org\/10.1002\/ajh.27519","journal-title":"Am J Hematol"},{"key":"3987_CR74","doi-asserted-by":"publisher","unstructured":"Chen X, Zhang B, Huang Y, Chen Y, Yang Y (2025) Post-marketing safety evaluation of zanubrutinib: a real-world pharmacovigilance analysis based on the FAERS database. Expert Opin Drug Saf 1\u201310. https:\/\/doi.org\/10.1080\/14740338.2025.2465872","DOI":"10.1080\/14740338.2025.2465872"},{"issue":"12","key":"3987_CR75","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA (2019) Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 94(12):1353\u20131363. https:\/\/doi.org\/10.1002\/ajh.25638","journal-title":"Am J Hematol"},{"issue":"5","key":"3987_CR76","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, Howlett C, Skarbnik A, Cheson BD, Zent C, Pu J, Kiselev P, Goy A, Claxton D, Isaac K, Kennard KH, Timlin C, Landsburg D, Winter A, Nasta SD, Bachow SH, Schuster SJ, Dorsey C, Svoboda J, Barr P, Ujjani CS (2018) Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica 103(5):874\u2013879. https:\/\/doi.org\/10.3324\/haematol.2017.182907","journal-title":"Haematologica"},{"issue":"11","key":"3987_CR77","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1038\/s41375-021-01252-y","volume":"35","author":"RR Furman","year":"2021","unstructured":"Furman RR, Byrd JC, Owen RG, O\u2019Brien SM, Brown JR, Hillmen P, Stephens DM, Chernyukhin N, Lezhava T, Hamdy AM, Izumi R, Patel P, Baek M, Christian B, Dyer M, Streetly MJ, Sun C, Rule S, Wang M, Ghia P, Jurczak W, Pagel JM, Sharman JP (2021) Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia 35(11):3201\u20133211. https:\/\/doi.org\/10.1038\/s41375-021-01252-y","journal-title":"Leukemia"},{"issue":"2","key":"3987_CR78","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.3324\/haematol.2019.220590","volume":"105","author":"T Flinsenberg","year":"2020","unstructured":"Flinsenberg T, Tromedjo CC, Hu N, Liu Y, Guo Y, Thia K, Noori T, Song X, Aw YH, Tantalo DG, Handunnetti S, Seymour JF, Roberts AW, Ritchie D, Koldej R, Neeson PJ, Wang L, Trapani JA, Tam CS, Voskoboinik I (2020) Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. Haematologica 105(2):e76\u2013e79. https:\/\/doi.org\/10.3324\/haematol.2019.220590","journal-title":"Haematologica"},{"key":"3987_CR79","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2021-148544","volume":"138","author":"M Shadman","year":"2021","unstructured":"Shadman M, Flinn IW, Levy MY, Porter R, Burke JM, Cultrera JL, Misleh J, Zafar SF, Freeman B, Rao SS, Yimer H, Chaudhry A, Gandhi MD, Guthrie TH, Kingsley E, Tumula PK, Manda S, Chen D, Cohen A, By K, Xu L, Liu Y, Sharman JP (2021) Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients (Pts) with relapsed\/refractory B-cell malignancies. Blood 138:1410","journal-title":"Blood"},{"issue":"7","key":"3987_CR80","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","volume":"24","author":"DW Denning","year":"2024","unstructured":"Denning DW (2024) Global incidence and mortality of severe fungal disease. Lancet Infect Dis 24(7):e428\u2013e438. https:\/\/doi.org\/10.1016\/S1473-3099(23)00692-8","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"3987_CR81","doi-asserted-by":"publisher","first-page":"E174","DOI":"10.1002\/ajh.25816","volume":"95","author":"A Colado","year":"2020","unstructured":"Colado A, Marin FJ, Elias EE, Amondarain M, Vergara RM, Sarapura MV, Cordini G, Fuentes F, Balboa L, Fernandez GH, Pavlovsky M, Bezares F, Morande P, Giordano M, Gamberale R, Borge M (2020) Second generation BTK inhibitors impair the anti-fungal response of macrophages and neutrophils. Am J Hematol 95(7):E174\u2013E178. https:\/\/doi.org\/10.1002\/ajh.25816","journal-title":"Am J Hematol"},{"issue":"8","key":"3987_CR82","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1177\/10781552221087730","volume":"28","author":"D Patel","year":"2022","unstructured":"Patel D, Sidana M, Mdluli X, Patel V, Stapleton A, Dasanu CA (2022) A fatal disseminated Cryptococcal infection in a patient treated with zanubrutinib for waldenstrom\u2019s macroglobulinemia. J Oncol Pharm Pract 28(8):1917\u20131921. https:\/\/doi.org\/10.1177\/10781552221087730","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"3987_CR83","doi-asserted-by":"publisher","first-page":"8255","DOI":"10.3390\/curroncol30090599","volume":"30","author":"G Maggioni","year":"2023","unstructured":"Maggioni G, Fedrigo M, Visentin A, Carturan E, Ruocco V, Trentin L, Alaibac M, Angelini A (2023) Severe fatal mucormycosis in a patient with chronic lymphocytic leukaemia treated with zanubrutinib: a case report and review of the literature. Curr Oncol 30(9):8255\u20138265. https:\/\/doi.org\/10.3390\/curroncol30090599","journal-title":"Curr Oncol"},{"issue":"6","key":"3987_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.7564","volume":"11","author":"M Walsh","year":"2023","unstructured":"Walsh M, Xu A, Ballas Z, Sanchez R (2023) Disseminated fungal infection in a patient receiving zanubrutinib. Clin Case Rep 11(6):e7564. https:\/\/doi.org\/10.1002\/ccr3.7564","journal-title":"Clin Case Rep"},{"issue":"10","key":"3987_CR85","doi-asserted-by":"publisher","first-page":"e084991","DOI":"10.1136\/bmjopen-2024-084991","volume":"14","author":"J Wang","year":"2024","unstructured":"Wang J, Zheng X, Lin J, Huang J, Zhang M, Huang P, Yang X (2024) Real-world safety profile of zanubrutinib: a disproportionality analysis based on the FAERS database. BMJ Open 14(10):e084991. https:\/\/doi.org\/10.1136\/bmjopen-2024-084991","journal-title":"BMJ Open"},{"key":"3987_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051103","author":"P von Hundelshausen","year":"2021","unstructured":"von Hundelshausen P, Siess W (2021) Bleeding by Bruton tyrosine kinase-inhibitors: dependency on drug type and disease. Cancers. https:\/\/doi.org\/10.3390\/cancers13051103","journal-title":"Cancers"},{"issue":"10","key":"3987_CR87","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1182\/blood-2003-04-1142","volume":"102","author":"BT Atkinson","year":"2003","unstructured":"Atkinson BT, Ellmeier W, Watson SP (2003) Tec regulates platelet activation by GPVI in the absence of Btk. Blood 102(10):3592\u20133599. https:\/\/doi.org\/10.1182\/blood-2003-04-1142","journal-title":"Blood"},{"issue":"3","key":"3987_CR88","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1055\/s-0039-1677744","volume":"119","author":"V Denzinger","year":"2019","unstructured":"Denzinger V, Busygina K, Jamasbi J, Pekrul I, Spannagl M, Weber C, Lorenz R, Siess W (2019) Optimizing platelet GPVI inhibition versus haemostatic impairment by the Btk inhibitors Ibrutinib, Acalabrutinib, ONO\/GS-4059, BGB-3111 and evobrutinib. Thromb Haemost 119(3):397\u2013406. https:\/\/doi.org\/10.1055\/s-0039-1677744","journal-title":"Thromb Haemost"},{"issue":"3","key":"3987_CR89","doi-asserted-by":"publisher","first-page":"240","DOI":"10.21147\/j.issn.1000-9604.2024.03.02","volume":"36","author":"Z Song","year":"2024","unstructured":"Song Z, Jiang D, Yu L, Chen Y, Zhou D, Li Y, Wu D, Zhang L, Miao L, Ma J, Zhu J, Jing H, Zhao R (2024) Evidence-based expert consensus on clinical management of safety of Bruton\u2019s tyrosine kinase inhibitors (2024). Chin J Cancer Res 36(3):240\u2013256. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2024.03.02","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"3987_CR90","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41420-022-00927-4","volume":"8","author":"Z Yin","year":"2022","unstructured":"Yin Z, Zou Y, Wang D, Huang X, Xiong S, Cao L, Zhang Y, Sun Y, Zhang N (2022) Regulation of the tec family of non-receptor tyrosine kinases in cardiovascular disease. Cell Death Discov 8(1):119. https:\/\/doi.org\/10.1038\/s41420-022-00927-4","journal-title":"Cell Death Discov"},{"issue":"25","key":"3987_CR91","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","volume":"124","author":"JR McMullen","year":"2014","unstructured":"McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS (2014) Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 124(25):3829\u20133830. https:\/\/doi.org\/10.1182\/blood-2014-10-604272","journal-title":"Blood"},{"issue":"25","key":"3987_CR92","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","volume":"142","author":"L Xiao","year":"2020","unstructured":"Xiao L, Salem JE, Clauss S, Hanley A, Bapat A, Hulsmans M, Iwamoto Y, Wojtkiewicz G, Cetinbas M, Schloss MJ, Tedeschi J, Lebrun-Vignes B, Lundby A, Sadreyev RI, Moslehi J, Nahrendorf M, Ellinor PT, Milan DJ (2020) Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. Circulation 142(25):2443\u20132455. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.049210","journal-title":"Circulation"},{"issue":"22","key":"3987_CR93","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood.2019000840","volume":"134","author":"T Dickerson","year":"2019","unstructured":"Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, Guha A, Rogers KA, Bhat S, Byrd JC, Woyach JA, Awan F, Addison D (2019) Hypertension and incident cardiovascular events following ibrutinib initiation. Blood 134(22):1919\u20131928. https:\/\/doi.org\/10.1182\/blood.2019000840","journal-title":"Blood"},{"issue":"1","key":"3987_CR94","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40959-021-00125-8","volume":"7","author":"JC Avalon","year":"2021","unstructured":"Avalon JC, Fuqua J, Miller T, Deskins S, Wakefield C, King A, Inderbitzin-Brooks S, Bianco C, Veltri L, Fang W, Craig M, Kanate A, Ross K, Malla M, Patel B (2021) Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with ibrutinib. Cardio-Oncology 7(1):38. https:\/\/doi.org\/10.1186\/s40959-021-00125-8","journal-title":"Cardio-Oncology"},{"issue":"1","key":"3987_CR95","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luad172","volume":"2","author":"I Sontag","year":"2024","unstructured":"Sontag I, Bergmann L, Adamek HE (2024) Severe hyperglycemia due to protein kinase inhibitor therapy in a patient with poorly controlled diabetes mellitus. JCEM Case Rep 2(1):luad172. https:\/\/doi.org\/10.1210\/jcemcr\/luad172","journal-title":"JCEM Case Rep"},{"issue":"5","key":"3987_CR96","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s10840-022-01400-z","volume":"66","author":"M Fazal","year":"2023","unstructured":"Fazal M, Wei C, Chuy KL, Hussain K, Gomez SE, Ba SS, Pietrasik G, Yadav N, Ghazizadeh Z, Kapoor R, Witteles RM, Blackmon A, Wang PJ, John RM, Narayan SM, Cheng P, Rhee JW, Baykaner T (2023) Tyrosine kinase inhibitor-associated ventricular arrhythmias: a case series and review of literature. J Interv Card Electrophysiol 66(5):1165\u20131175. https:\/\/doi.org\/10.1007\/s10840-022-01400-z","journal-title":"J Interv Card Electrophysiol"},{"key":"3987_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.941633","volume":"12","author":"L Wang","year":"2022","unstructured":"Wang L, Tang J, Feng J, Huang Y, Cheng Y, Xu H, Miao Y (2022) Case report: Zanubrutinib-induced dermatological toxicities: a single-center experience and review. Front Oncol 12:941633. https:\/\/doi.org\/10.3389\/fonc.2022.941633","journal-title":"Front Oncol"},{"issue":"6","key":"3987_CR98","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","volume":"21","author":"V Sibaud","year":"2020","unstructured":"Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L (2020) Dermatological toxicities of bruton\u2019s tyrosine kinase inhibitors. Am J Clin Dermatol 21(6):799\u2013812. https:\/\/doi.org\/10.1007\/s40257-020-00535-x","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"3987_CR99","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1634\/theoncologist.12-5-610","volume":"12","author":"TJ Lynch","year":"2007","unstructured":"Lynch TJ, Kim ES, Eaby B, Garey J, West DP, Lacouture ME (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12(5):610\u2013621. https:\/\/doi.org\/10.1634\/theoncologist.12-5-610","journal-title":"Oncologist"},{"issue":"3","key":"3987_CR100","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrg758","volume":"3","author":"E Fuchs","year":"2002","unstructured":"Fuchs E, Raghavan S (2002) Getting under the skin of epidermal morphogenesis. Nat Rev Genet 3(3):199\u2013209. https:\/\/doi.org\/10.1038\/nrg758","journal-title":"Nat Rev Genet"},{"issue":"9","key":"3987_CR101","doi-asserted-by":"publisher","first-page":"e708","DOI":"10.1016\/S2352-3026(24)00213-8","volume":"11","author":"S Belkaid","year":"2024","unstructured":"Belkaid S, Amini-Adle M (2024) Zanubrutinib-associated ecchymotic lesions. Lancet Haematol 11(9):e708. https:\/\/doi.org\/10.1016\/S2352-3026(24)00213-8","journal-title":"Lancet Haematol"},{"issue":"5","key":"3987_CR102","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jth.13651","volume":"15","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel JJ, Olson SR, Tao DL, McCarty O, Danilov AV, DeLoughery TG (2017) Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost 15(5):835\u2013847. https:\/\/doi.org\/10.1111\/jth.13651","journal-title":"J Thromb Haemost"},{"issue":"12","key":"3987_CR103","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1161\/CIRCRESAHA.121.318259","volume":"128","author":"MR Fleming","year":"2021","unstructured":"Fleming MR, Xiao L, Jackson KD, Beckman JA, Barac A, Moslehi JJ (2021) Vascular impact of cancer therapies: the case of BTK (Bruton tyrosine Kinase) inhibitors. Circ Res 128(12):1973\u20131987. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318259","journal-title":"Circ Res"},{"key":"3987_CR104","unstructured":"U.S. Food and Drug Administration. Approval label for JAYPIRCA\u00ae(Revised:6\/2024). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216059s002lbl.pdf."},{"key":"3987_CR105","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014975","author":"NN Shah","year":"2025","unstructured":"Shah NN, Zinzani PL, Wang ML, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss BJ, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve M, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada PB, Cheah CY (2025) Pirtobrutinib, a highly Selective, Non-covalent (Reversible) BTKi in R\/R follicular lymphoma: phase 1\/2 BRUIN study. Blood Adv. https:\/\/doi.org\/10.1182\/bloodadvances.2024014975","journal-title":"Blood Adv"},{"issue":"9","key":"3987_CR106","doi-asserted-by":"publisher","first-page":"e682","DOI":"10.1016\/S2352-3026(24)00172-8","volume":"11","author":"WG Wierda","year":"2024","unstructured":"Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P (2024) Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1\/2 BRUIN study. Lancet Haematol 11(9):e682\u2013e692. https:\/\/doi.org\/10.1016\/S2352-3026(24)00172-8","journal-title":"Lancet Haematol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03987-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03987-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03987-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:04:36Z","timestamp":1771859076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03987-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3987"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03987-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}